Mefloquine is a chiral molecule with two asymmetric carbon centres, which means it has four different stereoisomers . The drug is currently manufactured and sold as a racemate of the ( R , S )- and ( S , R )-enantiomers by Hoffman-LaRoche , a Swiss pharmaceutical company. Essentially, it is two drugs in one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer. 
In October 2008, the European Medicines Agency recommended the suspension of Acomplia after the Committee for Medicinal Products for Human Use (CHMP) had determined that the risks of Acomplia outweighed its benefits due to the risk of serious psychiatric problems, including suicide.  In November 2008 an advisory committee in Brazil recommended suspension as well, and that month Sanofi-Aventis suspended sale of the drug worldwide.  The EMA approval was withdrawn in January 2009.   In 2009 India prohibited the manufacture and sale of the drug.